Cargando…
Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?
Since the introduction of the 13-valent pneumococcal conjugate vaccine, a number of studies have demonstrated the limited efficacy of the pneumococcal serotype 3 component of this vaccine. Evidence from seven countries (Denmark, France, Greece, Portugal, Sweden, UK, US) shows limited or no effective...
Autores principales: | Linley, Ezra, Bell, Abigail, Gritzfeld, Jenna F., Borrow, Ray |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466091/ https://www.ncbi.nlm.nih.gov/pubmed/30609868 http://dx.doi.org/10.3390/vaccines7010004 |
Ejemplares similares
-
Pneumococcal Serotype–specific Unresponsiveness in Vaccinated Child with Cochlear Implant
por: Stanford, Elaine, et al.
Publicado: (2012) -
Serotype-specific Cardiac Involvement in Pneumococcal Pneumonia
por: Klugman, Keith P, et al.
Publicado: (2020) -
Optimal Serotype Compositions for Pneumococcal Conjugate Vaccination under Serotype Replacement
por: Nurhonen, Markku, et al.
Publicado: (2014) -
Persistence of Pneumococcal Serotype 3 in Adult Pneumococcal Disease in Hong Kong
por: Subramanian, Reema, et al.
Publicado: (2021) -
Pneumococcal serotype evolution in Western Europe
por: Tin Tin Htar, Myint, et al.
Publicado: (2015)